NTRA vs. WST: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at NTRA and WST, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | NTRA | WST |
|---|---|---|
| Company Name | Natera, Inc. | West Pharmaceutical Services, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 23.62 billion USD | 19.27 billion USD |
| Exchange | NasdaqGS | NYSE |
| Listing Date | July 1, 2015 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of NTRA and WST by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | NTRA | WST |
|---|---|---|
| 5-Day Price Return | 7.42% | -1.91% |
| 13-Week Price Return | 6.39% | 18.46% |
| 26-Week Price Return | 24.06% | 21.80% |
| 52-Week Price Return | 34.24% | -7.74% |
| Month-to-Date Return | 6.91% | 2.13% |
| Year-to-Date Return | 8.71% | -18.20% |
| 10-Day Avg. Volume | 1.22M | 0.62M |
| 3-Month Avg. Volume | 1.27M | 0.67M |
| 3-Month Volatility | 39.08% | 54.29% |
| Beta | 1.65 | 1.16 |
Profitability
Return on Equity (TTM)
NTRA
-22.21%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
NTRA has a negative Return on Equity of -22.21%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
WST
17.66%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.51%
- Median
- 6.47%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, WST’s Return on Equity of 17.66% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
NTRA
-12.89%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
NTRA has a negative Net Profit Margin of -12.89%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
WST
16.48%
Life Sciences Tools & Services Industry
- Max
- 32.18%
- Q3
- 18.30%
- Median
- 10.19%
- Q1
- 4.20%
- Min
- -2.05%
WST’s Net Profit Margin of 16.48% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin (TTM)
NTRA
-14.95%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
NTRA has a negative Operating Profit Margin of -14.95%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
WST
19.65%
Life Sciences Tools & Services Industry
- Max
- 38.39%
- Q3
- 21.40%
- Median
- 13.57%
- Q1
- 8.38%
- Min
- -3.51%
WST’s Operating Profit Margin of 19.65% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | NTRA | WST |
|---|---|---|
| Return on Equity (TTM) | -22.21% | 17.66% |
| Return on Assets (TTM) | -15.03% | 13.10% |
| Net Profit Margin (TTM) | -12.89% | 16.48% |
| Operating Profit Margin (TTM) | -14.95% | 19.65% |
| Gross Profit Margin (TTM) | 62.86% | 35.27% |
Financial Strength
Current Ratio (MRQ)
NTRA
3.72
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
NTRA’s Current Ratio of 3.72 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
WST
2.78
Life Sciences Tools & Services Industry
- Max
- 3.46
- Q3
- 2.78
- Median
- 1.91
- Q1
- 1.53
- Min
- 0.43
WST’s Current Ratio of 2.78 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
NTRA
0.06
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
NTRA’s Debt-to-Equity Ratio of 0.06 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
WST
0.07
Life Sciences Tools & Services Industry
- Max
- 1.35
- Q3
- 0.74
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
Falling into the lower quartile for the Life Sciences Tools & Services industry, WST’s Debt-to-Equity Ratio of 0.07 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
NTRA
-57.80
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
NTRA has a negative Interest Coverage Ratio of -57.80. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
WST
130.12
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 130.12, WST demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
Financial Strength at a Glance
| Symbol | NTRA | WST |
|---|---|---|
| Current Ratio (MRQ) | 3.72 | 2.78 |
| Quick Ratio (MRQ) | 3.44 | 2.08 |
| Debt-to-Equity Ratio (MRQ) | 0.06 | 0.07 |
| Interest Coverage Ratio (TTM) | -57.80 | 130.12 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
WST
0.31%
Life Sciences Tools & Services Industry
- Max
- 1.41%
- Q3
- 0.65%
- Median
- 0.35%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Yield of 0.31% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
Dividend Payout Ratio (TTM)
NTRA
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
NTRA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
WST
12.32%
Life Sciences Tools & Services Industry
- Max
- 113.14%
- Q3
- 61.34%
- Median
- 17.74%
- Q1
- 0.00%
- Min
- 0.00%
WST’s Dividend Payout Ratio of 12.32% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | NTRA | WST |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.31% |
| Dividend Payout Ratio (TTM) | 0.00% | 12.32% |
Valuation
Price-to-Earnings Ratio (TTM)
NTRA
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for NTRA is currently unavailable.
WST
39.27
Life Sciences Tools & Services Industry
- Max
- 75.35
- Q3
- 51.00
- Median
- 32.93
- Q1
- 25.27
- Min
- 1.43
WST’s P/E Ratio of 39.27 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
NTRA
12.04
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
NTRA’s P/S Ratio of 12.04 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
WST
6.47
Life Sciences Tools & Services Industry
- Max
- 10.49
- Q3
- 6.43
- Median
- 4.66
- Q1
- 2.88
- Min
- 1.08
WST’s P/S Ratio of 6.47 is in the upper echelon for the Life Sciences Tools & Services industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
NTRA
18.51
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
NTRA’s P/B Ratio of 18.51 is in the upper tier for the Biotechnology industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
WST
5.37
Life Sciences Tools & Services Industry
- Max
- 6.69
- Q3
- 5.00
- Median
- 3.46
- Q1
- 2.38
- Min
- 0.93
WST’s P/B Ratio of 5.37 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
Valuation at a Glance
| Symbol | NTRA | WST |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | 39.27 |
| Price-to-Sales Ratio (TTM) | 12.04 | 6.47 |
| Price-to-Book Ratio (MRQ) | 18.51 | 5.37 |
| Price-to-Free Cash Flow Ratio (TTM) | 226.11 | 55.68 |